Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria
Why the study?
Does amlodipine, valsartan, or their combination improve endothelial function and biomarker levels in diabetic CKD stage I patients with hypertension?
Population
108 diabetic CKD stage I patients with hypertension, mean age 46.7+/-5.3 years, 56% men.
Comparison
Amlodipine, valsartan, or their combination for… vs Active comparators.
Design
RCT
Follow-up
12 weeks
Authors
Discussion
Loading...
Member takes
Implication
These biomarkers may track endothelial responses to antihypertensives in diabetic CKD; extends their validation as surrogates in RCT data.
Structured PICO
Does amlodipine, valsartan, or their combination improve endothelial function and biomarker levels in diabetic CKD stage I patients with hypertension?
P
Population
108 diabetic CKD stage I patients with hypertension, mean age 46.7+/-5.3 years, 56% men.
I
Intervention
Amlodipine (10 mg/d), valsartan (160 mg/d), or their combination for 12 weeks.
C
Comparator
Active comparators (amlodipine alone, valsartan alone, or their combination).
O
Outcome
Changes in flow-mediated dilation (FMD), proteinuria, sTWEAK, and PTX3 plasma levels.surrogate
Antihypertensive therapy with amlodipine, valsartan, or their combination improves endothelial function and normalizes sTWEAK and PTX3 biomarkers in diabetic patients with early CKD and hypertension.
Cite This Study
Yılmaz et al. (2010) studied this question.